NORD Urges Congress: Don’t Cut Orphan Drug Tax Credit
This week, the National Organization of Rare Disorders (NORD) and more than 70 patient organizations sent a letter to key members of Congress in support of maintaining the Orphan Drug Tax Credit....
View ArticleMito What???
Mitochondrial Disease: The Most Common Disease You’ve Probably Never Heard of… About 20 years ago, mitochondrial disease was virtually unheard of. Just 10 years ago, it was considered rare. Today,...
View ArticleComplexities of Rare Diseases Take the Spotlight at BIO
Global Genes Founder & CEO Nicole Boice opened the BIO 2015 Orphan & Rare Disease Track by addressing a packed session with a simple, powerful statement: “We’re all working to eliminate the...
View ArticleOrphan Drug Tax Credit is Crucial to Rare Disease R&D
The term “rare disease” may be misleading: to be “rare” a disease must effect fewer than 200,000 people in the U.S., but there are over 7,000 rare diseases that have been identified. Taken together,...
View ArticleThe Washington Post Unfairly Attacks The Orphan Drug Act
The Orphan Drug Act has been a tremendous success and addressed a market failure by providing incentives to bring new treatments to those suffering with rare diseases. That’s why I was deeply troubled...
View ArticleNORD President: Congress must act now to help 15 million sick children
Writing in The Hill, National Organization for Rare Disorders (NORD) President and CEO Peter Saltonstall called upon Congress to act swiftly to maintain an important program encouraging research into...
View ArticleNORD and the Orphan Drug Act Celebrate 35 Years Driving Rare Disease...
The National Organization for Rare Disorders (NORD) has been instrumental in influencing public policy, regulatory frameworks, research, and economic discussions around rare diseases and orphan drugs....
View Article
More Pages to Explore .....